嵌合抗原受体 T 细胞疗法的神经系统并发症。
Neurological Complications of CAR T Cell Therapy.
机构信息
Department of Hematology/Oncology, Larner College of Medicine at the University of Vermont, Burlington, VT, USA.
Department of Neurological Sciences, Larner College of Medicine at the University of Vermont, Burlington, VT, USA.
出版信息
Curr Oncol Rep. 2020 Jul 1;22(8):83. doi: 10.1007/s11912-020-00935-6.
PURPOSE OF REVIEW
Chimeric antigen receptor (CAR) T cells are a breakthrough therapeutic treatment for patients with relapsed and refractory hematologic malignancies. With two FDA-approved formulations and likely more to come, CAR T cell therapy is moving beyond clinical trials and into academic and community oncology practices throughout the country. Oncologists are tasked with understanding the indications for this treatment and the potential complications.
RECENT FINDINGS
In this review, we focus on the neurological toxicities associated with CAR T cell therapy. Neurotoxicity affects approximately half of patients treated with CAR T cells and can cause severe morbidity. We discuss the incidence, pathophysiology, and management of neurological complications of CAR T cells. CAR T cells are a breakthrough treatment for hematologic malignancies with considerable neurological toxicity that requires attention and management.
目的综述
嵌合抗原受体 (CAR) T 细胞是治疗复发/难治性血液系统恶性肿瘤患者的突破性疗法。目前已有两种 FDA 批准的 CAR-T 细胞疗法，并且可能还会有更多产品问世，CAR-T 细胞疗法正从临床试验走向全美学术和社区肿瘤学实践。肿瘤学家的任务是了解该疗法的适应证和潜在并发症。
最近的发现
在本综述中，我们重点关注与 CAR-T 细胞治疗相关的神经毒性。神经毒性影响约一半接受 CAR-T 细胞治疗的患者，并可导致严重的发病率。我们讨论了 CAR-T 细胞治疗相关神经并发症的发生率、发病机制和管理。CAR-T 细胞是血液系统恶性肿瘤的突破性治疗方法，但具有相当大的神经毒性，需要引起关注和管理。
Zotero 插件